Related Experiment Video
Updated: May 15, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Recommendations for the management of tyrosinaemia type 1
Corinne de Laet1, Carlo Dionisi-Vici, James V Leonard
1Nutrition and Metabolism Unit, Department of Pediatrics, University Children’s Hospital Queen Fabiola, Brussels, Belgium.
Abstract:
The management of tyrosinaemia type 1 (HT1, fumarylacetoacetase deficiency) has been revolutionised by the introduction of nitisinone but dietary treatment remains essential and the management is not easy. In this review detailed recommendations for the management are made based on expert opinion, published case reports and investigational studies as the evidence base is limited and there are no prospective controlled studies.The added value of this paper is that it summarises in detail current clinical knowledge about HT1 and makes recommendations for the management.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Inborn Errors of Metabolism
Type I Diabetes I: Introduction
Diabetes Mellitus: Type 2 and Gestational
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
